Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Interventions
an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers
Drug · Other
Lead sponsor
Ayu, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Chronic Ulcer of Lower Extremity
Interventions
Contact Ultrasound Therapy, Noncontact Ultrasound Therapy
Device
Lead sponsor
Texas Health Resources
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetic Foot Ulcer
Interventions
TWO2 Device, Placebo Device
Device
Lead sponsor
AOTI Ltd.
Industry
Eligibility
18 Years to 89 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Vacaville, California • Washington D.C., District of Columbia + 6 more
Conditions
Venous Ulcer
Interventions
Autologous Platelet Gel (APG)
Procedure
Lead sponsor
National Healing Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
6
States / cities
St. Petersburg, Florida • Titusville, Florida • Newburyport, Massachusetts + 3 more
Completed No phase listed Observational Results available

Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

NCT03257254
Conditions
Venous Leg Ulcer
Interventions
Varithena
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Timeline
2017 – 2020
U.S. locations
13
States / cities
Palo Alto, California • Sacramento, California • Darien, Connecticut + 10 more
Conditions
Diabetic Foot Ulcer
Interventions
Esmolol hydrochloride, Placebo gel
Drug
Lead sponsor
Novalead Pharma Private Limited
Industry
Eligibility
18 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, PuraPly AM, PuraPly XT
Other · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Clevland, Ohio
Conditions
Neuropathic Diabetic Ulcer - Foot
Interventions
RedDress Wound Care System (RD1)
Device
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Miami, Florida • North Miami Beach, Florida • Pittsburgh, Pennsylvania + 1 more
Conditions
Varicose Ulcer
Interventions
PDGF-B/Ad5
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Nivolumab, Varlilumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Conditions
Venous Leg Ulcer (VLU)
Interventions
Topical Wound Oxygen Therapy, Sham Control Topical Wound Oxygen
Device
Lead sponsor
AOTI Ltd.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions
Deferoxamine Product, Placebo
Drug · Other
Lead sponsor
TauTona Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more
Conditions
Foot Ulcer, Diabetic
Interventions
GrafixPRIME®, Dressing Application, Off-loading (walking boot)
Other · Procedure · Device
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Arizona City, Arizona • California City, California • New Mexico, New Mexico
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers

NCT01208220
Conditions
Pressure Ulcer, Soft Tissue Necrosis Lower Limb
Interventions
Negative Pressure Wound Therapy, Collagenase Ointment
Device · Biological
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Shreveport, Louisiana
Conditions
Chronic Venous Hypertension With Ulcer
Interventions
Standard Multi-layered Compression dressing, Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)
Procedure
Lead sponsor
Solsys Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Diabetic Foot Ulcers
Interventions
Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant
Combination Product
Lead sponsor
Omeza, LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Toledo, Ohio
Conditions
Diabetic Foot Ulcer
Interventions
InnovaMatrix AC porcine placental ECM therapy
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
North Port, Florida • Buffalo, New York • Monroeville, Pennsylvania + 2 more
Conditions
Foot Ulcer, Diabetic
Interventions
PriMatrix Moist Wound Therapy, Standard of Care Moist Wound Therapy
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
15
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 11 more
Conditions
Pressure Ulcer, Venous Ulcer, Diabetic Ulcer, Surgical Wound, Trauma Wound
Interventions
PuraPly™ Antimicrobial Wound Matrix
Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mineola, New York
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Conditions
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Estar Medical dba Medical Technologies, LTD
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Corpus Christi, Texas
Conditions
Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
Interventions
AMG0001, Placebo
Biological
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Carlsbad, California • Downey, California • Fresno, California + 16 more
Conditions
Venous Leg Ulcer
Interventions
NeoThelium FT (HCT/P 361)
Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Metairie, Louisiana • Slidell, Louisiana